MB1707
/ Mainline Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 21, 2023
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Mainline Biosciences, Inc. | Not yet recruiting ➔ Withdrawn
Metastases • Trial withdrawal • Breast Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor
July 20, 2022
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
(clinicaltrials.gov)
- P1 | N=6 | Not yet recruiting | Sponsor: Mainline Biosciences, Inc.
New P1 trial • Breast Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor
1 to 2
Of
2
Go to page
1